NCT01700621View on ClinicalTrials.gov

Coadministration of Measles-rubella and Rotavirus Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

482

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Measles Antibody SeroconversionRubella Antibody SeroconversionRotavirus Geometric Mean Titer (GMT)Rotavirus Immunoglobulin A (IgA) Seropositivity
Interventions
BIOLOGICAL

Rotarix vaccine

one 1.0 ml dose of oral rotavirus vaccine at 9 months of age

BIOLOGICAL

measles-rubella vaccine

one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine

Trial Locations (1)

Unknown

ICDDR,B, Dhaka

All Listed Sponsors
lead

PATH

OTHER

NCT01700621 - Coadministration of Measles-rubella and Rotavirus Vaccines | Biotech Hunter | Biotech Hunter